These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 25988935

  • 21. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F, Abellan Alfocea P, Ortega Suazo EJ, López Garrido MA, Becerra Massare A, Gila Medina AM, Redondo Cerezo E, Espinosa Aguilar MD.
    Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
    [Abstract] [Full Text] [Related]

  • 22. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, Jaenigen B, Rentsch M, Wolters H, Rath T, Cingöz T, Benck U, Banas B, Hugo C.
    Lancet; 2016 Dec 17; 388(10063):3006-3016. PubMed ID: 27871759
    [Abstract] [Full Text] [Related]

  • 23. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.
    Gruber SA, Garnick J, Morawski K, Sillix DH, West MS, Granger DK, El-Amm JM, Alangaden GJ, Chandrasekar P, Haririan A.
    Clin Transplant; 2005 Apr 17; 19(2):273-8. PubMed ID: 15740567
    [Abstract] [Full Text] [Related]

  • 24. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
    Miura M, Harada H, Fukuzawa N, Iwami D, Taniguchi A, Seki T, Togashi M, Ogawa Y, Satoh H, Hirano T.
    Clin Transplant; 2005 Apr 17; 19 Suppl 14():54-8. PubMed ID: 15955170
    [Abstract] [Full Text] [Related]

  • 25. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
    Nanmoku K, Kurosawa A, Kubo T, Shinzato T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2017 Oct 17; 49(8):1724-1728. PubMed ID: 28923615
    [Abstract] [Full Text] [Related]

  • 26. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
    Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Takeda A, Iwasaki K, Uchida K, Kobayashi T.
    Int Immunopharmacol; 2016 Oct 17; 39():192-198. PubMed ID: 27491025
    [Abstract] [Full Text] [Related]

  • 27. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M, Snowsill T, Jones-Hughes T, Crathorne L, Cooper C, Varley-Campbell J, Mujica-Mota R, Coelho H, Huxley N, Lowe J, Dudley J, Marks S, Hyde C, Bond M, Anderson R.
    Health Technol Assess; 2016 Aug 17; 20(61):1-324. PubMed ID: 27557331
    [Abstract] [Full Text] [Related]

  • 28. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
    Andrade-Sierra J, Heredia-Pimentel A, Rojas-Campos E, Ramírez Flores D, Cerrillos-Gutierrez JI, Miranda-Díaz AG, Evangelista-Carrillo LA, Martínez-Martínez P, Jalomo-Martínez B, Gonzalez-Espinoza E, Gómez-Navarro B, Medina-Pérez M, Nieves-Hernández JJ.
    Int J Infect Dis; 2021 Jun 17; 107():18-24. PubMed ID: 33862205
    [Abstract] [Full Text] [Related]

  • 29. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group.
    N Engl J Med; 2006 Nov 09; 355(19):1967-77. PubMed ID: 17093248
    [Abstract] [Full Text] [Related]

  • 30. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.
    Health Technol Assess; 2005 May 09; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [Abstract] [Full Text] [Related]

  • 31. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2018 May 09; 50(4):1050-1055. PubMed ID: 29631750
    [Abstract] [Full Text] [Related]

  • 32. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.
    Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS.
    Am J Transplant; 2011 Nov 09; 11(11):2453-62. PubMed ID: 21812923
    [Abstract] [Full Text] [Related]

  • 33. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 09; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 34. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S.
    Pharmacotherapy; 2011 Jun 09; 31(6):566-73. PubMed ID: 21923440
    [Abstract] [Full Text] [Related]

  • 35. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug 09; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 36. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb 09; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 37. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M.
    Transplant Proc; 2009 May 09; 41(4):1175-7. PubMed ID: 19460509
    [Abstract] [Full Text] [Related]

  • 38. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar 09; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

  • 39. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O, Mathew JM, Shetty A, Bontha SV, Maluf DG, El Kassis Y, Park SH, Han J, Ansari MJ, Leventhal JR, Mas V, Gallon L.
    PLoS One; 2019 Mar 09; 14(5):e0216300. PubMed ID: 31136582
    [Abstract] [Full Text] [Related]

  • 40. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, Moore J, Allwood M, Lowe J, Hyde C, Hoyle M, Bond M, Anderson R.
    Health Technol Assess; 2016 Aug 09; 20(62):1-594. PubMed ID: 27578428
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.